CompletedNCT00481195
Armodafinil added to treatment for bipolarity type I depression
About this title
Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Read the official source — NCT00481195Medication studyAges 18–65Multiple countries
Understand this study
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Birmingham and 54 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateJune 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 257
- Sponsor
- Cephalon
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Bulgaria, Hungary, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00481195
- Official title
Show the full official title
An 8 Week Double Blind, Placebo-Controlled, Parallel Group, Fixed Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Birmingham, United States · Escondido, United States · Lafayette, United States
43 more locations
- National City, United States
- Oceanside, United States
- Orange, United States
- Pico Rivera, United States
- Riverside, United States
- San Diego, United States
- Stanford, United States
- Jacksonville, United States
- Lauderhill, United States
- Tampa, United States
- West Palm Beach, United States
- Atlanta, United States
- Smyrna, United States
- Skokie, United States
- Rockville, United States
- Clementon, United States
- Brooklyn, United States
- New York, United States
- Staten Island, United States
- Raleigh, United States
- Winston-Salem, United States
- Cleveland, United States
- Dayton, United States
- Oklahoma City, United States
- Salem, United States
- DuBois, United States
- Norristown, United States
- Philadelphia, United States
- Memphis, United States
- Austin, United States
- Bellaire, United States
- Irving, United States
- Wichita Falls, United States
- Bellevue, United States
- Kirkland, United States
- Burgas, Bulgaria
- Plovdiv, Bulgaria
- Sofia, Bulgaria
- Budapest, Hungary
- Nagykálló, Hungary
- Bucharest, Romania
- Piteşti, Romania
- Targoviste, Romania
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Cephalon.
Did this study involve medication?
Yes. The study involved medication, including Armodafinil and Placebo.
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
